title: Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication.
abstract: OBJECTIVE
  To evaluate the efficacy of two commonly employed treatments for Helicobacter pylori infection and the impact of bacterial resistance to antibiotics on eradication rate.
  
  
  METHODS
  Ninety-two consecutive H. pylori-positive patients with active peptic ulcer disease were randomly enrolled to receive a 7-day treatment with either lansoprazole 30 mg plus amoxicillin 1 g and clarithromycin 500 mg [all twice a day (b.i.d.), Group A, n = 46]; or bismuth subcitrate 125 mg four times a day (q.i.d.) plus tetracycline 500 mg q.i.d and furazolidone 200 mg b.i.d. (Group B, n = 46) H. pylori status was reassessed 30 days after completion of the therapy and bacterial resistance to the antibiotics was investigated using an in vitro assay.
  
  
  RESULTS
  Five patients from each study group were lost to follow up. Both treatments resulted in similar H. pylori eradication rate: 66-60% (per protocol), 59-52% (intention-to-treat) in Groups A and B, respectively (non significant). However, eradication improved to 79% in the absence of H. pylori resistance to clarithromycin or amoxicillin.
  
  
  CONCLUSIONS
  Primary resistance to clarithromycin or amoxicillin may underscore a potentially serious problem for the eradication of H. pylori infection. Testing for bacterial resistance may become necessary to improve therapeutic efficacy.
authors.affiliation: Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil.
authors.forename: C
authors.initials: C
authors.lastname: Ecclissato
authors.forename: M A M
authors.initials: MA
authors.lastname: Marchioretto
authors.forename: S
authors.initials: S
authors.lastname: Mendonça
authors.forename: A P O
authors.initials: AP
authors.lastname: Godoy
authors.forename: R A
authors.initials: RA
authors.lastname: Guersoni
authors.forename: M
authors.initials: M
authors.lastname: Deguer
authors.forename: H
authors.initials: H
authors.lastname: Piovesan
authors.forename: J G P
authors.initials: JG
authors.lastname: Ferraz
authors.forename: J
authors.initials: J
authors.lastname: Pedrazzoli
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents